Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis

•COVID-19 patients with pneumonitis benefit from antiviral treatment.•Early remdesivir treatment accelerates the decline in SARS-CoV-2 respiratory concentration.•The significant viral load decline was observed from day 8 onwards after admission.

Saved in:
Bibliographic Details
Published in:The Journal of infection 2022-12, Vol.85 (6), p.702-769
Main Authors: Lai, Christopher KC, Lui, Grace CY, Wei, Yuchen, Chong, Ka Chun, Chen, Zigui, Ling, Lowell, Ng, Rita WY, Boon, Siaw SS, Ho, Wendy CS, Yeung, Apple CM, Hui, David SC, Chan, Paul KS
Format: Article
Language:English
Subjects:
Anti-viral
Antiviral Agents - therapeutic use
Clinical
COVID-19
COVID-19 Drug Treatment
Humans
Letter to the Editor
Pneumonia - drug therapy
Remdesivir
Respiratory System
RNA, Viral
SARS-CoV-2
Treatment
Viral kinetics
Viral Load
Virological
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•COVID-19 patients with pneumonitis benefit from antiviral treatment.•Early remdesivir treatment accelerates the decline in SARS-CoV-2 respiratory concentration.•The significant viral load decline was observed from day 8 onwards after admission.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2022.08.031